Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupropion/naltrexone - Currax Pharmaceuticals

Next Previous
X
Search
Drug Profile

Bupropion/naltrexone - Currax Pharmaceuticals

Alternative Names: Bupropion/naltrexone; Contrave; CX-101; Mysimba; Naltrexone HCl/ bupropion HCl prolonged release; Naltrexone HCl/bupropion HCl; Naltrexone HCl/bupropion HCl extended release; Naltrexone SR/bupropion SR; Naltrexone XR/bupropion XR; Naltrexone/bupropion; NB32

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orexigen Therapeutics
  • Developer Bausch Health Companies; Biologix FZCo; Kwang Dong Pharmaceutical; Orexigen Therapeutics; Orexigen Therapeutics [CEASED]; Rovi
  • Class Analgesics; Antidepressants; Drug withdrawal therapies; Ethers; Irritable bowel syndrome therapies; Ketones; Morphine derivatives; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Opioid mu receptor antagonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Obesity

Highest Development Phases

  • Marketed Obesity
  • Phase II Smoking withdrawal
  • No development reported Depressive disorders

Most Recent Events

  • 27 Feb 2024 Launched for Obesity in Canada prior to February 2024 (PO)
  • 27 Feb 2024 Launched for Obesity in Poland prior to February 2024 (PO)
  • 29 Oct 2021 Bupropion/naltrexone is still in Phase II development for Smoking withdrawal

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top